flunarizine therapy in reducing vertigo symptoms among patients with vestibular migraine.
Not Applicable
Completed
- Conditions
- Health Condition 1: H818- Other disorders of vestibular function
- Registration Number
- CTRI/2019/09/021185
- Lead Sponsor
- Farnaz Nasrin ISlam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 31
Inclusion Criteria
Patients diagnosed as migraine as per ICH 3beta criteria above 18 years for the initial screening
Patients with vestibular migraine will be screened as per ICH 3beta criteria
Patients with vestibular migraine will be included for VEMP and further follow-up
Exclusion Criteria
Patients accounting for other causes of headache
Patients with other vestibular dysfunctions
Patients with hearing loss
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients diagnosed as vestibular migraine as per ICH 3beta criteria will be assessed clinically and initial VEMP TEST will be carried out. Patient will be started with Flunarizine. Patients will be followed up VEMP will be repeated at 2 monthsTimepoint: Initial VEMP test will be done followed by VEMP after 2 months of Flunarizine therapy to assess any objective and subjective improvement
- Secondary Outcome Measures
Name Time Method Clinical improvement in vestibular symptoms after Flunarizine therapyTimepoint: Initial assessment and monthly follow-up for 2 months;Specific changes in VEMPsTimepoint: Initial VEMP and VEMP after 2months of Flunarizine therapy